DR. SIMEON E GOLDBLUM, MD
Osteopathic Medicine at Greene St, Baltimore, MD
License number
Maryland D35863
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
22 S Greene St, Baltimore, MD 21201
Phone
(410) 706-5504
(410) 706-5508 (Fax)
(410) 706-5508 (Fax)
Personal information
See more information about SIMEON E GOLDBLUM at radaris.comName
Address
Phone
7130 Pheasant Cross Dr, Baltimore, MD 21209
419 Redwood St, Baltimore, MD 21201
419 Redwood, Street, MD 21154
Organization information
See more information about SIMEON E GOLDBLUM at bizstanding.comUniversity Of Maryland - Simeon E Goldblum MD
20 Penn St #351, Baltimore, MD 21201
Categories:
Infectious Disease Physicians & Surgeons
Phone:
(410) 706-7562 (Phone)
Professional information
See more information about SIMEON E GOLDBLUM at trustoria.com
Simeon E Goldblum, Baltimore MD
Simeon E Goldblum, Baltimore MD
Specialties:
Infectious Disease Specialist
Address:
22 S Greene St, Baltimore, MD 21201
20 Penn St, Baltimore, MD 21201
20 Penn St, Baltimore, MD 21201
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Dr. Simeon E Goldblum, Baltimore MD - MD (Doctor of Medicine)
Dr. Simeon E Goldblum, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
22 S Greene St SUITE 10, Baltimore 21201
(410) 328-5793 (Phone), (410) 706-5508 (Fax)
20 Penn St, Baltimore 21201
THE MUCOSAL BIOLOGY RESEARCH
20 Penn St SUITE 351, Baltimore 21201
(410) 706-5501 (Phone), (410) 328-1072 (Fax)
UNIVERSITY OF MARYLAND MEDICAL CENTER
22 S Greene St, Baltimore 21201
(410) 328-6971 (Phone), (410) 328-8326 (Fax)
Baltimore Office
22 S Greene St, Baltimore 21201
(410) 328-6971 (Phone), (410) 328-8326 (Fax)
(410) 328-5793 (Phone), (410) 706-5508 (Fax)
20 Penn St, Baltimore 21201
THE MUCOSAL BIOLOGY RESEARCH
20 Penn St SUITE 351, Baltimore 21201
(410) 706-5501 (Phone), (410) 328-1072 (Fax)
UNIVERSITY OF MARYLAND MEDICAL CENTER
22 S Greene St, Baltimore 21201
(410) 328-6971 (Phone), (410) 328-8326 (Fax)
Baltimore Office
22 S Greene St, Baltimore 21201
(410) 328-6971 (Phone), (410) 328-8326 (Fax)
Certifications:
Infectious Disease, 1978, Internal Medicine, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
22 S Greene St SUITE 10, Baltimore 21201
20 Penn St, Baltimore 21201
UNIVERSITY OF MARYLAND MEDICAL CENTER
22 S Greene St, Baltimore 21201
THE MUCOSAL BIOLOGY RESEARCH
20 Penn St SUITE 351, Baltimore 21201
Baltimore Office
22 S Greene St, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
20 Penn St, Baltimore 21201
UNIVERSITY OF MARYLAND MEDICAL CENTER
22 S Greene St, Baltimore 21201
THE MUCOSAL BIOLOGY RESEARCH
20 Penn St SUITE 351, Baltimore 21201
Baltimore Office
22 S Greene St, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
Education:
Medical School
University of Pittsburgh / Main Campus
Graduated: 1973
Montefiore M C H&L Moses Division
University Hospital
University of Pittsburgh / Main Campus
Graduated: 1973
Montefiore M C H&L Moses Division
University Hospital
Simeon Emanuel Goldblum, Baltimore MD
Simeon Emanuel Goldblum, Baltimore MD
Specialties:
Internal Medicine, Infectious Disease, Critical Care Medicine, Pulmonary Disease, Critical Care Medicine
Work:
University of Maryland
22 S Greene St, Baltimore, MD 21263 University of Maryland
419 W Redwood St, Baltimore, MD 21201 Baltimore Veterans Affairs Medical Center
10 N Greene St, Baltimore, MD 21201
22 S Greene St, Baltimore, MD 21263 University of Maryland
419 W Redwood St, Baltimore, MD 21201 Baltimore Veterans Affairs Medical Center
10 N Greene St, Baltimore, MD 21201
Education:
University of Pittsburgh(1973)
Professor Of Med At U Of Md
Professor Of Med At U Of Md
Position:
professor of med at u of md
Location:
Baltimore, Maryland Area
Industry:
Research
Work:
u of md
-
professor of med
Method Of Treating Inflammation With Inhibitors Of Sialyl Transferases
Method Of Treating Inflammation With Inhibitors Of Sialyl Transferases
US Patent:
2006007, Apr 6, 2006
Filed:
Oct 6, 2005
Appl. No.:
11/244551
Inventors:
Alan Cross - Chevy Chase MD, US
Nicholas Stamatos - Baltimore MD, US
Simeon Goldblum - Baltimore MD, US
Nicholas Stamatos - Baltimore MD, US
Simeon Goldblum - Baltimore MD, US
International Classification:
A61K 31/7072
US Classification:
514049000
Abstract:
Provided herein are a methods of reducing a level of activity of a sialyl transferase enzyme, a sialidase enzyme or a combination thereof using inhibitors of these enzymes, for example specific inhibitory compound or antibodies directed against the enzymes. The methods are effective to treat an inflammatory disease or disorder or a primary or metastatic cancer. Also provided is a method for screening potential inhibitors of sialyl transferase enzymes.
Egfr And Par2 Regulation Of Intestinal Permeability
Egfr And Par2 Regulation Of Intestinal Permeability
US Patent:
2012010, May 3, 2012
Filed:
Dec 12, 2011
Appl. No.:
13/323100
Inventors:
Alessio Fasano - West Friendship MD, US
Karen Manon Lammers - Baltimore MD, US
Terez Shea-Donohue - Chevy Chase MD, US
Simeon Goldblum - Baltimore MD, US
Craig Sturgeon - Severna Park MD, US
Karen Manon Lammers - Baltimore MD, US
Terez Shea-Donohue - Chevy Chase MD, US
Simeon Goldblum - Baltimore MD, US
Craig Sturgeon - Severna Park MD, US
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD
International Classification:
A61K 39/395, A61P 37/06, G01N 33/53, A61K 31/7105, C12Q 1/68
US Classification:
4241721, 514 44 A, 435 61, 436501, 435 71
Abstract:
The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR).